(Q64980814)

2 July 2019

title

Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells. (English)

1 reference

2 July 2019

1 reference

0 references

Taewan Kim

1 reference

2 July 2019

Taehyung Kim

1 reference

2 July 2019

Soonyoung Choi

1 reference

2 July 2019

Hyeran Ko

1 reference

2 July 2019

Deokbae Park

1 reference

2 July 2019

Youngki Lee

1 reference

2 July 2019

publication date

30 June 2018

1 reference

2 July 2019

Development & Reproduction

published in

1 reference

2 July 2019

volume

1 reference

2 July 2019

issue

1 reference

2 July 2019

page(s)

133-142

1 reference

2 July 2019

Creative Commons Attribution-NonCommercial 3.0 Unported

start time

1 June 2018

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors

1 reference

12 December 2020

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

1 reference

12 December 2020

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

1 reference

12 December 2020

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

12 December 2020

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

1 reference

12 December 2020

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

12 December 2020

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

1 reference

12 December 2020

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

12 December 2020

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

12 December 2020

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

1 reference

12 December 2020

Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis

1 reference

12 December 2020

Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types

1 reference

12 December 2020

Diabetes and risk of bladder cancer: evidence from a case-control study in New England

1 reference

12 December 2020

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

1 reference

12 December 2020

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

1 reference

12 December 2020

The AMPK signalling pathway coordinates cell growth, autophagy and metabolism

1 reference

12 December 2020

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy

1 reference

12 December 2020

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

1 reference

12 December 2020

Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer

1 reference

12 December 2020

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.

1 reference

12 December 2020

Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan.

1 reference

12 December 2020

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

1 reference

12 December 2020

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

1 reference

12 December 2020

Repositioning metformin for cancer prevention and treatment

1 reference

12 December 2020

Metformin: a potential therapeutic agent for recurrent colon cancer

1 reference

12 December 2020

Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling

1 reference

12 December 2020

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma

1 reference

12 December 2020

Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression

1 reference

12 December 2020

Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis

1 reference

12 December 2020

Combinational strategies of metformin and chemotherapy in cancers

1 reference

12 December 2020

Blockage of Autophagy Rescues the Dual PI3K/mTOR Inhibitor BEZ235-induced Growth Inhibition of Colorectal Cancer Cells

1 reference

12 December 2020

RAS and BRAF in metastatic colorectal cancer management

1 reference

12 December 2020

Colorectal cancer statistics, 2017.

1 reference

12 December 2020

Metformin Synergistically Potentiates the Antitumor Effects of Imatinib in Colorectal Cancer Cells

1 reference

12 December 2020

10.12717/DR.2018.22.2.133

Identifiers

DOI

1 reference

2 July 2019

PMC publication ID

6048307

1 reference

2 July 2019

PubMed publication ID

30023463

1 reference

2 July 2019